JP2015519403A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519403A5
JP2015519403A5 JP2015517461A JP2015517461A JP2015519403A5 JP 2015519403 A5 JP2015519403 A5 JP 2015519403A5 JP 2015517461 A JP2015517461 A JP 2015517461A JP 2015517461 A JP2015517461 A JP 2015517461A JP 2015519403 A5 JP2015519403 A5 JP 2015519403A5
Authority
JP
Japan
Prior art keywords
region
controlled release
mucosa
release polymer
mucoadhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519403A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/045976 external-priority patent/WO2013188819A2/en
Publication of JP2015519403A publication Critical patent/JP2015519403A/ja
Publication of JP2015519403A5 publication Critical patent/JP2015519403A5/ja
Pending legal-status Critical Current

Links

JP2015517461A 2012-06-14 2013-06-14 活性剤送達のための粘膜付着性デバイス Pending JP2015519403A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261659784P 2012-06-14 2012-06-14
US201261659781P 2012-06-14 2012-06-14
US61/659,784 2012-06-14
US61/659,781 2012-06-14
US201261671287P 2012-07-13 2012-07-13
US61/671,287 2012-07-13
PCT/US2013/045976 WO2013188819A2 (en) 2012-06-14 2013-06-14 Mucoadhesive devices for delivery of active agents

Publications (2)

Publication Number Publication Date
JP2015519403A JP2015519403A (ja) 2015-07-09
JP2015519403A5 true JP2015519403A5 (enExample) 2016-07-14

Family

ID=48748504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517461A Pending JP2015519403A (ja) 2012-06-14 2013-06-14 活性剤送達のための粘膜付着性デバイス

Country Status (5)

Country Link
US (4) US20150174076A1 (enExample)
EP (1) EP2861220A2 (enExample)
JP (1) JP2015519403A (enExample)
CA (1) CA2915358A1 (enExample)
WO (1) WO2013188819A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3191083T3 (da) * 2014-09-11 2021-04-19 Gelita Ag Gelatine-/pektinpartikler
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
WO2017136745A1 (en) * 2016-02-05 2017-08-10 Entrega Inc. Oral dosage form with drying agent for delivery of active agent
CA3015172A1 (en) 2016-02-18 2017-08-24 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
ITUA20161822A1 (it) * 2016-03-18 2017-09-18 Indena Spa Composizioni utili nella prevenzione e/o nel trattamento di patologie del cavo orale, delle prime vie aeree e dell’esofago
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
MX382197B (es) 2017-01-23 2025-03-13 Afyx Therapeutics As Metodo para la fabricacion de un producto de dos capas basado en fibras electrohiladas.
WO2018151849A1 (en) * 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
CA3063711A1 (en) 2017-05-17 2018-11-22 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
CN110809464A (zh) * 2017-06-27 2020-02-18 株式会社培旺精廉宅 粘膜附着性口服制剂
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
EP3793667A1 (en) 2018-05-17 2021-03-24 Massachusetts Institute of Technology Systems for electrical stimulation
WO2020160399A1 (en) 2019-02-01 2020-08-06 Massachusetts Institute Of Technology Systems and methods for liquid injection
MX2022001865A (es) 2019-08-12 2022-03-11 Massachusetts Inst Technology Articulos y metodos para la administracion de agentes terapeuticos.
US11793980B2 (en) 2019-08-31 2023-10-24 Celero Systems, Inc. Intestinal attachment device
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
KR20230170674A (ko) 2021-03-15 2023-12-19 이피토미 메디칼 엘티디 활성제를 조직으로 전달하기 위한 확장가능한 디바이스
CN117580570A (zh) 2021-06-01 2024-02-20 派沃技术公司 增强的两阶段微粒基局部治疗性递送系统
US20260027062A1 (en) 2022-03-03 2026-01-29 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins
WO2024062466A1 (en) 2022-09-21 2024-03-28 Epitomee Medical Ltd. Controllably disintegrable self-expandable ingestible devices

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56100714A (en) * 1980-01-16 1981-08-12 Teijin Ltd Pharmaceutical adhering to oral mucous membrane or nasal mucous membrane
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US6159497A (en) * 1998-10-30 2000-12-12 Noven Pharmaceuticals, Inc. Patch applicator
AU2002319653A1 (en) * 2001-07-20 2003-03-03 Samir Mitragotri Method for oral drug delivery
WO2003066572A1 (en) * 2002-02-07 2003-08-14 Wisconsin Alumni Research Foundation Polyamine compounds and compositions for use in conjunction with cancer therapy
AU2004259209A1 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
BRPI0711168A2 (pt) * 2006-05-02 2011-08-23 Panacea Biotec Ltd composição transmucosal
JP5005422B2 (ja) * 2007-05-09 2012-08-22 株式会社エンプラス 射出成形ギヤ
BR112013011942A2 (pt) * 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
JP6139506B2 (ja) * 2011-04-04 2017-05-31 コロプラスト アクティーゼルスカブ 接着パッチ

Similar Documents

Publication Publication Date Title
PH12015501756A1 (en) Tamper resistant pharmaceutical formulations
CL2014002283A1 (es) Forma de dosificacion oral solida de liberacion inmediata que comprende particulas que comprenden un nucleo con un primer agente activo, un recubrimiento con un segundo agente activo sobre el y un material sensible al ph acido sobre dicho nucleo recubierto; proceso para prepararla; metodo de tratamiento; y uso para tratar dolor.
JP2011157405A5 (enExample)
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
UY34705A (es) Películas de capas múltiples capaces de liberar ingredientes activos por un período limitado de tiempo
WO2014102613A3 (en) Device for disposal and neutralization of pharmaceutical agents
AR073704A1 (es) Sistema de administracion transdermal de droga para principios activos liquidos que tiene una capa de matriz adhesiva que incluye un ingrediente farmaceutico activo que es seleccionado entre selegilina y rivastigmina
JP2012085643A5 (enExample)
CN110035744A (zh) 一种尼拉帕尼缓控释药物组合物及其用途
JP2014528431A5 (enExample)
PE20190105A1 (es) Formas de dosificacion de liberacion modificada disuasivas de abuso
PE20142035A1 (es) Formulacion compuesta que comprende un comprimido esferoidal de multiples unidades (must) encapsulada en una capsula dura y metodo para preparar la misma
CO6400184A2 (es) Formulaciones galénicas de compuestos orgánicos
JP2013047264A5 (enExample)
WO2014130866A3 (en) Targeted buccal delivery comprising cisplatin-loaded chitosan nanoparticles
RU2014148544A (ru) Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей
JP2014526519A5 (enExample)
JP2014514104A5 (enExample)
WO2015107544A3 (en) Pharmaceutical microemulsion immobilized in a thin polymer matrix and methods of making them
JP2008510713A5 (enExample)
JP2011251959A5 (enExample)
JP2012223563A5 (enExample)
WO2017123315A3 (en) Nanocrystals formed in a microenvironment
ES2606399T3 (es) Formulación sólida de liberación controlada para administración oral en un sobre de dosis única y método de preparación de la misma
WO2014184663A3 (en) Orally dispersible drug formulations